Back

Use of cardioprotective glucose lowering therapy before and after myocardial infarction among patients with type-2 diabetes: a nationwide registry study

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Diabetes and the heart (3) Diabetes and the Heart ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Ms Bashaaer Sharad

Lund University, Malmo (Sweden)

4 More presentations in this session

Presentation thumbnail
Progressive disease substrate in obese type 2 diabetic patients with coronary artery disease despite achieving HbA1c <7.0%: sub-analysis from the OPTIMAL randomized study
Doctor A. Salib (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
GLP-1 receptor agonists and SGLT2-inhibitors in patients with diabetes and ischaemic heart disease in primary care
Doctor T. Andersson (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
Tirzepatide and the risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials
Doctor E. Mansouri (Tehran, IR) Mr L. Barbosa (Belo Horizonte, BR)
Abstract Slides Video
Presentation thumbnail
The impact of age of onset and duration of Type 2 diabetes on life expectancy and serious health outcomes
Doctor J. Isufi (Gothenburg, SE)
Abstract Slides

Access the full session

Session thumbnail
Diabetes and the heart (3)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Real-life use of novel glucose lowering agents after acute myocardial infarction and stable coronary artery disease in patients with diabetes - experience from national use in the SWEDEHEART-registry
thumbnail
Congress Presentation
GLP-1 receptor agonists and SGLT2-inhibitors in patients with diabetes and ischaemic heart disease in primary care
thumbnail
Congress Presentation
Low utilization of GLP-1RAs and SGLT2i in high-risk cardiovascular patients with diabetes: nationwide insights from myocardial Infarction and stroke survivors

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources